BR112018076190A2 - ortólogos e sistemas crispr tipo vi - Google Patents
ortólogos e sistemas crispr tipo viInfo
- Publication number
- BR112018076190A2 BR112018076190A2 BR112018076190-7A BR112018076190A BR112018076190A2 BR 112018076190 A2 BR112018076190 A2 BR 112018076190A2 BR 112018076190 A BR112018076190 A BR 112018076190A BR 112018076190 A2 BR112018076190 A2 BR 112018076190A2
- Authority
- BR
- Brazil
- Prior art keywords
- systems
- orthologs
- targeting
- crispr type
- rna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
- C12N9/226—Class 2 CAS enzyme complex, e.g. single CAS protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
- C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
- C12Q2521/301—Endonuclease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351662P | 2016-06-17 | 2016-06-17 | |
| US201662351803P | 2016-06-17 | 2016-06-17 | |
| US62/351,662 | 2016-06-17 | ||
| US62/351,803 | 2016-06-17 | ||
| US201662376377P | 2016-08-17 | 2016-08-17 | |
| US62/376,377 | 2016-08-17 | ||
| US201662410366P | 2016-10-19 | 2016-10-19 | |
| US62/410,366 | 2016-10-19 | ||
| US201662432240P | 2016-12-09 | 2016-12-09 | |
| US62/432,240 | 2016-12-09 | ||
| US201762471792P | 2017-03-15 | 2017-03-15 | |
| US62/471,792 | 2017-03-15 | ||
| US201762484786P | 2017-04-12 | 2017-04-12 | |
| US62/484,786 | 2017-04-12 | ||
| PCT/US2017/038154 WO2017219027A1 (en) | 2016-06-17 | 2017-06-19 | Type vi crispr orthologs and systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018076190A2 true BR112018076190A2 (pt) | 2019-06-18 |
Family
ID=59295312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018076190-7A BR112018076190A2 (pt) | 2016-06-17 | 2017-06-19 | ortólogos e sistemas crispr tipo vi |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11788083B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3455357A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP7267013B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20190019168A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109642231A (cg-RX-API-DMAC7.html) |
| AU (4) | AU2017283713B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018076190A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3028158A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017219027A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (178)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016069124A1 (en) | 2014-09-15 | 2016-05-06 | Board Of Regents, The University Of Texas System | Improved single molecule peptide sequencing |
| GB2577626B (en) | 2011-06-23 | 2020-09-23 | Univ Texas | Identifying peptides at the single molecule level |
| US11435358B2 (en) | 2011-06-23 | 2022-09-06 | Board Of Regents, The University Of Texas System | Single molecule peptide sequencing |
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| WO2016073990A2 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| CA2986310A1 (en) | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
| US11911415B2 (en) | 2015-06-09 | 2024-02-27 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for improving transplantation |
| CA2999500A1 (en) | 2015-09-24 | 2017-03-30 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| AU2016359629B2 (en) | 2015-11-23 | 2023-03-09 | Ranjan BATRA | Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/Cas9 |
| WO2017165826A1 (en) | 2016-03-25 | 2017-09-28 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
| US11236313B2 (en) | 2016-04-13 | 2022-02-01 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
| US10337051B2 (en) | 2016-06-16 | 2019-07-02 | The Regents Of The University Of California | Methods and compositions for detecting a target RNA |
| WO2018005873A1 (en) * | 2016-06-29 | 2018-01-04 | The Broad Institute Inc. | Crispr-cas systems having destabilization domain |
| AU2017302551B2 (en) | 2016-07-26 | 2023-04-27 | The General Hospital Corporation | Variants of CRISPR from Prevotella and Francisella 1 (Cpf1) |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| JP2019532644A (ja) | 2016-09-30 | 2019-11-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Rna誘導型核酸修飾酵素及びその使用方法 |
| CA3038982A1 (en) | 2016-09-30 | 2018-04-05 | The Regents Of The University Of California | Rna-guided nucleic acid modifying enzymes and methods of use thereof |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| US12404514B2 (en) | 2016-12-09 | 2025-09-02 | The Broad Institute, Inc. | CRISPR-systems for modifying a trait of interest in a plant |
| KR102993694B1 (ko) | 2016-12-09 | 2026-07-22 | 더 브로드 인스티튜트, 인코퍼레이티드 | Crispr 이펙터 시스템 기반 진단 |
| EP3555297A1 (en) | 2016-12-19 | 2019-10-23 | Editas Medicine, Inc. | Assessing nuclease cleavage |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| WO2018129368A2 (en) | 2017-01-06 | 2018-07-12 | Editas Medicine, Inc. | Methods of assessing nuclease cleavage |
| KR20190123328A (ko) | 2017-03-09 | 2019-10-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 암 백신 |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| US11021740B2 (en) | 2017-03-15 | 2021-06-01 | The Broad Institute, Inc. | Devices for CRISPR effector system based diagnostics |
| US11174515B2 (en) | 2017-03-15 | 2021-11-16 | The Broad Institute, Inc. | CRISPR effector system based diagnostics |
| US11104937B2 (en) * | 2017-03-15 | 2021-08-31 | The Broad Institute, Inc. | CRISPR effector system based diagnostics |
| CN110959039B (zh) * | 2017-03-15 | 2025-03-14 | 博德研究所 | 新型cas13b直向同源物crispr酶和系统 |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
| US11618928B2 (en) | 2017-04-12 | 2023-04-04 | The Broad Institute, Inc. | CRISPR effector system based diagnostics for malaria detection |
| US12590288B2 (en) | 2017-04-12 | 2026-03-31 | The Broad Institute, Inc. | Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response |
| AU2018251801B2 (en) | 2017-04-12 | 2024-11-07 | Massachusetts Institute Of Technology | Novel type VI CRISPR orthologs and systems |
| WO2018195545A2 (en) | 2017-04-21 | 2018-10-25 | The General Hospital Corporation | Variants of cpf1 (cas12a) with altered pam specificity |
| US11499151B2 (en) | 2017-04-28 | 2022-11-15 | Editas Medicine, Inc. | Methods and systems for analyzing guide RNA molecules |
| WO2018208998A1 (en) | 2017-05-10 | 2018-11-15 | The Regents Of The University Of California | Directed editing of cellular rna via nuclear delivery of crispr/cas9 |
| US12226479B2 (en) | 2017-05-11 | 2025-02-18 | The General Hospital Corporation | Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| CN110997908A (zh) | 2017-06-09 | 2020-04-10 | 爱迪塔斯医药公司 | 工程化的cas9核酸酶 |
| EP3638218A4 (en) | 2017-06-14 | 2021-06-09 | The Broad Institute, Inc. | COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH |
| WO2019005886A1 (en) * | 2017-06-26 | 2019-01-03 | The Broad Institute, Inc. | CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS |
| US10392616B2 (en) | 2017-06-30 | 2019-08-27 | Arbor Biotechnologies, Inc. | CRISPR RNA targeting enzymes and systems and uses thereof |
| WO2019010422A1 (en) | 2017-07-07 | 2019-01-10 | The Broad Institute, Inc. | ANTIVIRAL THERAPY BASED ON THE CRISPR SYSTEM |
| EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| WO2019014581A1 (en) | 2017-07-14 | 2019-01-17 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE |
| EP3654993A4 (en) | 2017-07-17 | 2021-08-25 | The Broad Institute, Inc. | CELL ATLAS OF HEALTHY HUMAN COLUMN AND HUMAN COLUMN WITH COLITIS ULCEROSA |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| KR20200074104A (ko) | 2017-10-04 | 2020-06-24 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물 |
| JP2020537121A (ja) * | 2017-10-04 | 2020-12-17 | ザ・ブロード・インスティテュート・インコーポレイテッド | Crisprエフェクター系に基づく診断 |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| WO2019084062A1 (en) | 2017-10-23 | 2019-05-02 | The Broad Institute, Inc. | SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITION |
| US20200332272A1 (en) * | 2017-10-23 | 2020-10-22 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| CN117487776A (zh) | 2017-11-01 | 2024-02-02 | 加利福尼亚大学董事会 | Casz组合物和使用方法 |
| WO2019089808A1 (en) | 2017-11-01 | 2019-05-09 | The Regents Of The University Of California | Class 2 crispr/cas compositions and methods of use |
| WO2019089804A1 (en) | 2017-11-01 | 2019-05-09 | The Regents Of The University Of California | Casy compositions and methods of use |
| US12171783B2 (en) | 2017-11-13 | 2024-12-24 | The Broad Institute, Inc. | Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas |
| US11332736B2 (en) | 2017-12-07 | 2022-05-17 | The Broad Institute, Inc. | Methods and compositions for multiplexing single cell and single nuclei sequencing |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| EP3728576A4 (en) * | 2017-12-22 | 2021-11-24 | The Broad Institute, Inc. | CAS12B SYSTEMS, METHODS AND COMPOSITIONS FOR SPECIFIC EDITING OF RNA BASES |
| US20210108267A1 (en) * | 2017-12-22 | 2021-04-15 | The Broad Institute, Inc. | Crispr effector system based multiplex diagnostics |
| KR102857066B1 (ko) * | 2018-01-29 | 2025-09-08 | 더 브로드 인스티튜트, 인코퍼레이티드 | Crispr 이펙터 시스템 기반 진단 |
| CN108559738A (zh) * | 2018-02-12 | 2018-09-21 | 南昌大学 | 一种植物rna修饰和编辑的系统及方法 |
| DK3765616T3 (da) | 2018-03-14 | 2023-08-21 | Arbor Biotechnologies Inc | Nye enzymer og systemer målrettet crispr dna og rna |
| PL3765615T3 (pl) | 2018-03-14 | 2023-11-13 | Arbor Biotechnologies, Inc. | Nowe enzymy i układy crispr ukierunkowane na dna |
| US20210189386A1 (en) * | 2018-03-30 | 2021-06-24 | POiRT Systems Co., Ltd. | Nucleic acid construct, medicinal composition, anticancer agent, antiviral agent and antibacterial agent |
| CN108796036B (zh) * | 2018-04-03 | 2021-11-19 | 交弘生物科技(上海)有限公司 | 基于原核Argonaute蛋白的核酸检测方法及其应用 |
| WO2019204210A1 (en) | 2018-04-16 | 2019-10-24 | Georgia Tech Research Corporation | Mrna driven expression of rna editors for treatment of pathologies |
| CA3097857A1 (en) * | 2018-04-20 | 2019-10-24 | The Regents Of The University Of California | Fusion proteins and fusion ribonucleic acids for tracking and manipulating cellular rna |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| WO2019222555A1 (en) | 2018-05-16 | 2019-11-21 | Arbor Biotechnologies, Inc. | Novel crispr-associated systems and components |
| CN108546718B (zh) * | 2018-05-16 | 2021-07-09 | 康春生 | crRNA介导的CRISPR/Cas13a基因编辑系统在肿瘤细胞中的应用 |
| CN110527697B (zh) * | 2018-05-23 | 2023-07-07 | 中国科学院分子植物科学卓越创新中心 | 基于CRISPR-Cas13a的RNA定点编辑技术 |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| US20190390193A1 (en) * | 2018-06-23 | 2019-12-26 | John Lawrence Mee | Reversible method for sustainable human cognitive enhancement |
| SG11202011240YA (en) | 2018-06-26 | 2020-12-30 | Broad Inst Inc | Crispr/cas and transposase based amplification compositions, systems and methods |
| CA3102163A1 (en) | 2018-06-26 | 2020-01-02 | Massachusetts Institute Of Technology | Crispr effector system based amplification methods, systems, and diagnostics |
| SG11202012785VA (en) | 2018-06-26 | 2021-01-28 | Broad Inst Inc | Crispr double nickase based amplification compositions, systems, and methods |
| AU2019291918B2 (en) | 2018-06-29 | 2025-06-12 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| WO2020000454A1 (zh) * | 2018-06-29 | 2020-01-02 | 深圳市博奥康生物科技有限公司 | 一种表达LwCas13a基因的质粒、构建方法及其应用 |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| AU2019301750A1 (en) | 2018-07-12 | 2021-01-28 | Board Of Regents, The University Of Texas System | Molecular neighborhood detection by oligonucleotides |
| WO2020023488A1 (en) * | 2018-07-23 | 2020-01-30 | Board Of Regents, The University Of Texas System | Single molecule sequencing identification of post-translational modifications on proteins |
| JP6915820B2 (ja) * | 2018-07-25 | 2021-08-04 | 国立研究開発法人産業技術総合研究所 | 植物における標的dnaのメチル化を抑制する方法 |
| EP3830256A2 (en) * | 2018-07-31 | 2021-06-09 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| WO2020028729A1 (en) | 2018-08-01 | 2020-02-06 | Mammoth Biosciences, Inc. | Programmable nuclease compositions and methods of use thereof |
| WO2020041380A1 (en) | 2018-08-20 | 2020-02-27 | The Broad Institute, Inc. | Methods and compositions for optochemical control of crispr-cas9 |
| CN119193702A (zh) * | 2018-09-06 | 2024-12-27 | 加利福尼亚大学董事会 | 经由改造的adar募集的rna和dna碱基编辑 |
| WO2020072907A1 (en) | 2018-10-05 | 2020-04-09 | Board Of Regents, The University Of Texas System | Solid-phase n-terminal peptide capture and release |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| EP3650553B1 (en) * | 2018-11-07 | 2023-07-12 | Siemens Healthcare GmbH | Method for detection of specific nucleic acids |
| US12402610B2 (en) | 2018-11-09 | 2025-09-02 | The Broad Institute, Inc. | Methods and compositions for modulating innate lymphoid cell pathogenic effectors |
| US20220073987A1 (en) | 2018-11-14 | 2022-03-10 | The Broad Institute, Inc. | Crispr system based droplet diagnostic systems and methods |
| EP3880844A2 (en) | 2018-11-14 | 2021-09-22 | President And Fellows Of Harvard College | Multiplexing highly evolving viral variants with sherlock detection method |
| AU2019381258B2 (en) * | 2018-11-15 | 2024-02-01 | China Agricultural University | CRISPR-Cas12j enzyme and system |
| WO2020102659A1 (en) * | 2018-11-15 | 2020-05-22 | The Broad Institute, Inc. | G-to-t base editors and uses thereof |
| US20250043366A1 (en) | 2018-12-13 | 2025-02-06 | The Broad Institute, Inc. | Tiled assays using crispr-cas based detection |
| EP3931313A2 (en) | 2019-01-04 | 2022-01-05 | Mammoth Biosciences, Inc. | Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| CN113544267B (zh) * | 2019-01-14 | 2025-04-18 | 罗切斯特大学 | 使用CRISPR-Cas进行靶向核RNA裂解和聚腺苷酸化 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| US20220154258A1 (en) | 2019-03-14 | 2022-05-19 | The Broad Institute, Inc. | Crispr effector system based multiplex diagnostics |
| US12618101B2 (en) | 2019-03-14 | 2026-05-05 | The Broad Institute, Inc. | Sherlock assays for tick-borne diseases |
| US12534714B2 (en) | 2019-03-18 | 2026-01-27 | The Broad Institute, Inc. | Type VII CRISPR proteins and systems |
| WO2020191241A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| CN113939617A (zh) * | 2019-03-26 | 2022-01-14 | 北京大学 | 鉴定功能元件的方法 |
| US12637682B2 (en) | 2019-04-16 | 2026-05-26 | The Regents Of The University Of California | Protein translational control |
| CN109913502A (zh) * | 2019-04-16 | 2019-06-21 | 和元生物技术(上海)股份有限公司 | 一种Cas9-gRNA表达系统及其应用 |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
| KR20220012264A (ko) * | 2019-05-22 | 2022-02-03 | 시트로겐 인코포레이티드 | 미생물의 신속한 식별을 위한 장치 및 방법 |
| US20220259617A1 (en) | 2019-06-13 | 2022-08-18 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| WO2021011493A1 (en) * | 2019-07-12 | 2021-01-21 | Duke University | 3' utr crispr-dcas 13 engineering system and methods of using same |
| CN114402071A (zh) * | 2019-07-15 | 2022-04-26 | 新加坡国立大学 | 用于基因特异性脱甲基和激活的方法和组合物 |
| CN110819652A (zh) * | 2019-08-21 | 2020-02-21 | 山东金城生物药业有限公司 | 一种谷氨酸棒杆菌同时基因敲除及基因表达抑制的双功能系统及应用 |
| US20220333208A1 (en) | 2019-09-03 | 2022-10-20 | The Broad Institute, Inc. | Crispr effector system based multiplex cancer diagnostics |
| WO2021046243A2 (en) | 2019-09-03 | 2021-03-11 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| US20230025039A1 (en) | 2019-09-20 | 2023-01-26 | The Broad Institute, Inc. | Novel type vi crispr enzymes and systems |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
| CA3159799A1 (en) * | 2019-12-02 | 2021-06-10 | Prashant MALI | Engineering circular guide rnas |
| US11827880B2 (en) | 2019-12-02 | 2023-11-28 | Shape Therapeutics Inc. | Therapeutic editing |
| US20230340537A1 (en) | 2020-01-17 | 2023-10-26 | The Broad Institute, Inc. | Small type ii-d cas proteins and methods of use thereof |
| US20230078498A1 (en) * | 2020-02-07 | 2023-03-16 | University Of Rochester | Targeted Translation of RNA with CRISPR-Cas13 to Enhance Protein Synthesis |
| CN111337666B (zh) * | 2020-02-12 | 2021-04-02 | 山东大学 | I-motif重组介导的FRET探针及其原位成像癌细胞表面蛋白质同源二聚化的应用 |
| WO2021169980A1 (en) * | 2020-02-25 | 2021-09-02 | Shanghaitech University | Compositions and methods for detecting nucleic acid-protein interactions |
| JP7412586B2 (ja) * | 2020-02-28 | 2024-01-12 | ヒュイダジェネ・セラピューティックス・カンパニー・リミテッド | VI-E型及びVI-F型CRISPR-Casシステム並びにそれらの使用 |
| US20220228150A1 (en) | 2020-03-17 | 2022-07-21 | Gowtham THAKKU | Crispr system high throughput diagnostic systems and methods |
| US11453907B2 (en) | 2020-03-23 | 2022-09-27 | The Broad Institute, Inc. | Crispr effector system based coronavirus diagnostics |
| CA3177481A1 (en) | 2020-05-08 | 2021-11-11 | David R. Liu | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| JP7419168B2 (ja) * | 2020-06-10 | 2024-01-22 | 株式会社東芝 | 改変型piggyBacトランスポゼースのポリペプチド、それをコードするポリヌクレオチド、導入キャリア、キット、細胞のゲノムに目的配列を組込む方法及び細胞製造方法 |
| BR112023001272A2 (pt) | 2020-07-24 | 2023-04-04 | Massachusetts Gen Hospital | Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células |
| CN118109438A (zh) * | 2020-09-30 | 2024-05-31 | 辉大(上海)生物科技有限公司 | 工程化的CRISPR/Cas13系统及其用途 |
| WO2022068912A1 (en) | 2020-09-30 | 2022-04-07 | Huigene Therapeutics Co., Ltd. | Engineered crispr/cas13 system and uses thereof |
| WO2022188039A1 (en) | 2021-03-09 | 2022-09-15 | Huigene Therapeutics Co., Ltd. | Engineered crispr/cas13 system and uses thereof |
| EP4229202A4 (en) * | 2020-10-13 | 2025-10-01 | Brigham & Womens Hospital Inc | COMPOSITIONS AND METHODS TARGETING CIRC2082 FOR THE TREATMENT OF CANCER |
| US20230072431A1 (en) * | 2020-11-03 | 2023-03-09 | Science Solutions Llc | Novel class 2 crispr-cas rna-guided endonucleases |
| CN112430586B (zh) * | 2020-11-16 | 2021-09-07 | 珠海舒桐医疗科技有限公司 | 一种VI-B型CRISPR/Cas13基因编辑系统及其应用 |
| CA3203046A1 (en) * | 2020-12-22 | 2022-06-30 | Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) | Application of crispr/cas13 for therapy of rna virus and/or bacterium induced diseases |
| EP4276182A4 (en) * | 2021-01-05 | 2024-11-27 | Kawasaki Gakuen Educational Foundation | TRANSCRIPTION PRODUCT IN CELLS OF AN ORGANISM COMPRISING A TRANSFECTED RNA, HUMAN AND TOOL FOR PURIFYING AN ASSOCIATED COMPLEX |
| CN117043326A (zh) * | 2021-03-09 | 2023-11-10 | 阿伯生物技术公司 | 包含变体多肽的组合物及其用途 |
| US20220325298A1 (en) * | 2021-04-12 | 2022-10-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Crispr epigenetic therapeutics for pain management |
| WO2022245454A2 (en) | 2021-04-14 | 2022-11-24 | Kansas State University Research Foundation | Short multi-repeat rna targeting gene silencing |
| WO2022241029A1 (en) | 2021-05-11 | 2022-11-17 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| AU2022284804A1 (en) | 2021-06-01 | 2023-12-07 | Arbor Biotechnologies, Inc. | Gene editing systems comprising a crispr nuclease and uses thereof |
| US20230058054A1 (en) * | 2021-06-29 | 2023-02-23 | Huigene Therapeutics Co., Ltd. | Crispr/cas system and uses thereof |
| WO2023283622A1 (en) | 2021-07-08 | 2023-01-12 | Montana State University | Crispr-based programmable rna editing |
| EP4141112B1 (en) * | 2021-07-08 | 2025-06-11 | Korea Advanced Institute of Science and Technology | Rna expression regulation or editing method through activity control of cas13 protein |
| US11814689B2 (en) | 2021-07-21 | 2023-11-14 | Montana State University | Nucleic acid detection using type III CRISPR complex |
| EP4215612A1 (en) * | 2022-01-20 | 2023-07-26 | Sartorius Stedim Cellca GmbH | Genome editing with crispr/cas nucleases comprising collateral activity |
| CN115712847B (zh) * | 2022-11-21 | 2026-03-17 | 长江水利委员会长江科学院 | 一种基于强震监测数据的高拱坝模态参数自动识别方法 |
| EP4622662A1 (en) | 2022-11-23 | 2025-10-01 | Amber Bio Inc. | Gene-modifying endonucleases |
| US12435357B2 (en) | 2022-12-22 | 2025-10-07 | Kanso Diagnostics Ltd. | Diagnostic device for detecting a target nucleic acid molecule in a biological sample |
| US20260232844A1 (en) | 2023-02-15 | 2026-08-13 | Arbor Biotechnologies, Inc. | Gene editing method for inhibiting aberrant splicing in stathmin 2 (stmn2) transcript |
| WO2024226832A1 (en) * | 2023-04-25 | 2024-10-31 | Orgenesis Inc. | Ribonucleases for treating viral infections |
| WO2025006545A2 (en) * | 2023-06-27 | 2025-01-02 | The Regents Of The University Of California | Nuclease effector bound type-vi crispr enzymes |
| WO2025096250A1 (en) * | 2023-10-30 | 2025-05-08 | Cz Biohub Sf, Llc | Manipulating spatial rna localization |
| KR102891058B1 (ko) * | 2023-11-22 | 2025-11-26 | 한국화학연구원 | 피부 자극성 평가용 형광 리포터가 도입된 인간 피부 세포 시스템 |
| KR102877375B1 (ko) * | 2023-11-22 | 2025-10-30 | 한국화학연구원 | 세포질 상분리 현상 실시간 모니터링용 형광 표지인자가 도입된 인간 전분화능 줄기세포 모델 기반 독성 평가 시스템 |
| KR102877367B1 (ko) * | 2023-11-22 | 2025-10-29 | 한국화학연구원 | 흡입독성 평가용 형광 리포터가 도입된 인간 폐 세포 시스템 |
| WO2025171210A1 (en) | 2024-02-09 | 2025-08-14 | Arbor Biotechnologies, Inc. | Compositions and methods for gene editing via homology-mediated end joining |
| CN120775820B (zh) * | 2024-04-07 | 2026-06-02 | 南京诺唯赞生物科技股份有限公司 | Rna聚合酶变体 |
| WO2026015829A2 (en) | 2024-07-12 | 2026-01-15 | Arbor Biotechnologies, Inc. | Small reverse transcriptases and gene editing systems comprising such |
| WO2026015832A2 (en) | 2024-07-12 | 2026-01-15 | Arbor Biotechnologies, Inc. | Reverse transcriptases and gene editing systems comprising such |
Family Cites Families (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| DE3751873T2 (de) | 1986-04-09 | 1997-02-13 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| WO1990006376A1 (en) * | 1988-12-05 | 1990-06-14 | The Salk Institute For Biological Studies | Target nucleic acid amplification/detection systems |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| GB9114259D0 (en) | 1991-07-02 | 1991-08-21 | Ici Plc | Plant derived enzyme and dna sequences |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| AU670316B2 (en) | 1992-07-27 | 1996-07-11 | Pioneer Hi-Bred International, Inc. | An improved method of (agrobacterium)-mediated transformation of cultured soybean cells |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| KR960702518A (ko) | 1993-05-17 | 1996-04-27 | 린다 에스, 스티븐슨 | Hiv 감염 및 aids에 대한 리보자임 유전자 치료(ribozyme gene therapy for hiv infection and aids) |
| US5789156A (en) | 1993-06-14 | 1998-08-04 | Basf Ag | Tetracycline-regulated transcriptional inhibitors |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| AU698739B2 (en) | 1995-06-06 | 1998-11-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US5985662A (en) | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5846946A (en) | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
| GB9907461D0 (en) | 1999-03-31 | 1999-05-26 | King S College London | Neurite regeneration |
| GB9720465D0 (en) | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
| DE69836092T2 (de) | 1997-10-24 | 2007-05-10 | Invitrogen Corp., Carlsbad | Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen |
| US6750059B1 (en) | 1998-07-16 | 2004-06-15 | Whatman, Inc. | Archiving of vectors |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US7868149B2 (en) | 1999-07-20 | 2011-01-11 | Monsanto Technology Llc | Plant genome sequence and uses thereof |
| US6603061B1 (en) | 1999-07-29 | 2003-08-05 | Monsanto Company | Agrobacterium-mediated plant transformation method |
| EP1294863B1 (en) * | 2000-05-24 | 2009-07-08 | Third Wave Technologies, Inc. | Detection of rna |
| GB0024550D0 (cg-RX-API-DMAC7.html) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
| WO2003045304A2 (en) | 2001-09-26 | 2003-06-05 | Mayo Foundation For Medical Education And Research | Mutable vaccines |
| GB0125216D0 (en) | 2001-10-19 | 2001-12-12 | Univ Strathclyde | Dendrimers for use in targeted delivery |
| US20090100536A1 (en) | 2001-12-04 | 2009-04-16 | Monsanto Company | Transgenic plants with enhanced agronomic traits |
| CN1620508A (zh) | 2001-12-21 | 2005-05-25 | 牛津生物医学(英国)有限公司 | 转基因生物 |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| GB0220467D0 (en) | 2002-09-03 | 2002-10-09 | Oxford Biomedica Ltd | Composition |
| AU2003284388A1 (en) | 2002-11-01 | 2004-06-07 | New England Biolabs, Inc. | Organellar targeting of rna and its use in the interruption of environmental gene flow |
| AU2004257373B2 (en) | 2003-07-16 | 2011-03-24 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
| CN1882693B (zh) | 2003-09-15 | 2012-08-15 | 普洛体维生物治疗公司 | 聚乙二醇修饰的脂质化合物及其应用 |
| GB0325379D0 (en) | 2003-10-30 | 2003-12-03 | Oxford Biomedica Ltd | Vectors |
| CA2569664C (en) | 2004-06-07 | 2013-07-16 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| EP2397490B1 (en) | 2004-07-16 | 2013-09-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Vaccine constructs and combinations of vaccines designed to improve the breadth of the immune response to diverse strains and clades of HIV |
| GB0422877D0 (en) | 2004-10-14 | 2004-11-17 | Univ Glasgow | Bioactive polymers |
| US7838658B2 (en) | 2005-10-20 | 2010-11-23 | Ian Maclachlan | siRNA silencing of filovirus gene expression |
| JP5043672B2 (ja) | 2005-10-28 | 2012-10-10 | 田辺三菱製薬株式会社 | 新規細胞膜透過ペプチド |
| EP1948674A4 (en) | 2005-11-02 | 2009-02-04 | Protiva Biotherapeutics Inc | MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF |
| GB0526211D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
| US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| JP2008078613A (ja) | 2006-08-24 | 2008-04-03 | Rohm Co Ltd | 窒化物半導体の製造方法及び窒化物半導体素子 |
| US20100099858A1 (en) | 2006-09-28 | 2010-04-22 | Mirkin Chad A | Maximizing Oligonucleotide Loading on Gold Nanoparticle |
| US9309528B2 (en) | 2006-11-21 | 2016-04-12 | The Samuel Roberts Noble Foundation, Inc. | Biofuel production methods and compositions |
| WO2008149176A1 (en) | 2007-06-06 | 2008-12-11 | Cellectis | Meganuclease variants cleaving a dna target sequence from the mouse rosa26 locus and uses thereof |
| JP2011512326A (ja) | 2007-12-31 | 2011-04-21 | ナノコア セラピューティクス,インコーポレイテッド | 心不全の治療用のrna干渉 |
| EP2279254B1 (en) | 2008-04-15 | 2017-07-05 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
| WO2009147368A1 (en) | 2008-06-04 | 2009-12-10 | Medical Research Council | Peptides |
| BRPI0910198A2 (pt) | 2008-06-30 | 2016-01-12 | Silenseed Ltd | composição para administração a partir de um sítio local de um agente baseado em nucleotídeos e método para tratar um sujeito sofrendo de uma doença requerendo tratamento local com um agente baseado em nucleotídeo. |
| WO2010004594A1 (en) | 2008-07-08 | 2010-01-14 | S.I.F.I. Societa' Industria Farmaceutica Italiana S.P.A. | Ophthalmic compositions for treating pathologies of the posterior segment of the eye |
| WO2010053572A2 (en) | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| GB2465749B (en) | 2008-11-25 | 2013-05-08 | Algentech Sas | Plant cell transformation method |
| US20120047601A1 (en) | 2009-02-17 | 2012-02-23 | The Regents Of The University Of California | Method of Reducing Acetylation in Plants to Improve Biofuel Production |
| ES2613498T3 (es) | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos |
| EP2449106B1 (en) | 2009-07-01 | 2015-04-08 | Protiva Biotherapeutics Inc. | Compositions and methods for silencing apolipoprotein b |
| US20110027239A1 (en) | 2009-07-29 | 2011-02-03 | Tissue Genesis, Inc. | Adipose-derived stromal cells (asc) as delivery tool for treatment of cancer |
| US8927807B2 (en) | 2009-09-03 | 2015-01-06 | The Regents Of The University Of California | Nitrate-responsive promoter |
| US8889394B2 (en) | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
| US20120003201A1 (en) | 2010-04-21 | 2012-01-05 | Nicholas Susanne B | Vault agents for chronic kidney disease |
| US9567573B2 (en) | 2010-04-26 | 2017-02-14 | Sangamo Biosciences, Inc. | Genome editing of a Rosa locus using nucleases |
| US8372951B2 (en) | 2010-05-14 | 2013-02-12 | National Tsing Hua University | Cell penetrating peptides for intracellular delivery |
| CN102946907A (zh) | 2010-05-28 | 2013-02-27 | 牛津生物医学(英国)有限公司 | 慢病毒载体向脑的递送 |
| US9193827B2 (en) | 2010-08-26 | 2015-11-24 | Massachusetts Institute Of Technology | Poly(beta-amino alcohols), their preparation, and uses thereof |
| US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
| CA2831392C (en) | 2011-03-28 | 2020-04-28 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US20120295960A1 (en) | 2011-05-20 | 2012-11-22 | Oxford Biomedica (Uk) Ltd. | Treatment regimen for parkinson's disease |
| EP2751567B1 (en) | 2011-09-01 | 2019-05-08 | University of Iowa Research Foundation | Oligonucleotide-based probes for detection of bacterial nucleases |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| US20130185823A1 (en) | 2012-01-16 | 2013-07-18 | Academia Sinica | Mesoporous silica nanoparticle-mediated delivery of dna into arabidopsis root |
| ES2728782T3 (es) * | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| CN116622704A (zh) | 2012-07-25 | 2023-08-22 | 布罗德研究所有限公司 | 可诱导的dna结合蛋白和基因组干扰工具及其应用 |
| US8614194B1 (en) | 2012-07-25 | 2013-12-24 | Kaohsiung Medical University | Anionic cell penetrating peptide and its use for intracellular delivery |
| EP4397759A3 (en) | 2012-10-23 | 2024-10-09 | Toolgen Incorporated | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| WO2014093709A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| PT2931898E (pt) | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais |
| KR102955556B1 (ko) | 2012-12-12 | 2026-04-22 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물 |
| EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| MX380562B (es) | 2012-12-12 | 2025-03-12 | Broad Inst Inc | Modificaciones de sistemas, métodos y composiciones guía optimizadas para la manipulación de secuencias. |
| SG10201707569YA (en) | 2012-12-12 | 2017-10-30 | Broad Inst Inc | Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications |
| CN105209621B (zh) | 2012-12-12 | 2021-05-25 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| EP3064585B1 (en) | 2012-12-12 | 2020-02-05 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| US11332719B2 (en) | 2013-03-15 | 2022-05-17 | The Broad Institute, Inc. | Recombinant virus and preparations thereof |
| ES2777217T3 (es) | 2013-06-17 | 2020-08-04 | Broad Inst Inc | Suministro, modificación y optimización de sistemas de guía en tándem, métodos y composiciones para la manipulación de secuencias |
| WO2014204723A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions |
| JP6738728B2 (ja) | 2013-06-17 | 2020-08-19 | ザ・ブロード・インスティテュート・インコーポレイテッド | 肝臓ターゲティングおよび治療のためのCRISPR−Cas系、ベクターおよび組成物の送達および使用 |
| KR20250012194A (ko) | 2013-06-17 | 2025-01-23 | 더 브로드 인스티튜트, 인코퍼레이티드 | 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용 |
| EP3011033B1 (en) | 2013-06-17 | 2020-02-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
| SG11201510327TA (en) | 2013-06-17 | 2016-01-28 | Broad Inst Inc | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells |
| WO2014204725A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
| WO2015065964A1 (en) | 2013-10-28 | 2015-05-07 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof |
| US20150166984A1 (en) * | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| EP3835419A1 (en) * | 2013-12-12 | 2021-06-16 | The Regents of The University of California | Methods and compositions for modifying a single stranded target nucleic acid |
| WO2015089419A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
| US10513711B2 (en) * | 2014-08-13 | 2019-12-24 | Dupont Us Holding, Llc | Genetic targeting in non-conventional yeast using an RNA-guided endonuclease |
| DK3597740T3 (da) * | 2014-11-06 | 2022-06-20 | Dupont Us Holding Llc | Peptidmedieret indføring af rna-styret endonuklease i celler |
| US20170362580A1 (en) * | 2014-12-12 | 2017-12-21 | James Zhu | Methods and compositions for selectively eliminating cells of interest |
| CA3012631A1 (en) * | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| CN116814590A (zh) * | 2015-10-22 | 2023-09-29 | 布罗德研究所有限公司 | Vi-b型crispr酶和系统 |
| EP3390624A4 (en) * | 2015-12-18 | 2019-07-10 | The Regents of The University of California | Modified site-directed modifying polypeptides and methods of use thereof |
| MX2018008416A (es) * | 2016-01-08 | 2019-11-11 | Univ California | Polipéptidos heterodímericos condicionalmente activos y métodos para su uso. |
| WO2017123609A1 (en) * | 2016-01-12 | 2017-07-20 | The Regents Of The University Of California | Compositions and methods for enhanced genome editing |
| WO2017136335A1 (en) * | 2016-02-01 | 2017-08-10 | The Regents Of The University Of California | Self-inactivating endonuclease-encoding nucleic acids and methods of using the same |
| JP6998313B2 (ja) * | 2016-02-11 | 2022-02-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 細胞のゲノムにおける変異ジストロフィン遺伝子を修飾する方法及び組成物 |
| US20180112234A9 (en) * | 2016-03-14 | 2018-04-26 | Intellia Therapeutics, Inc. | Methods and compositions for gene editing |
| ES3030658T3 (en) * | 2016-03-30 | 2025-07-01 | Intellia Therapeutics Inc | Lipid nanoparticle formulations for crispr/cas components |
| WO2017173092A1 (en) * | 2016-03-31 | 2017-10-05 | The Regents Of The University Of California | Methods for genome editing in zygotes |
| WO2017189336A1 (en) * | 2016-04-25 | 2017-11-02 | The Regents Of The University Of California | Methods and compositions for genomic editing |
| US10337051B2 (en) * | 2016-06-16 | 2019-07-02 | The Regents Of The University Of California | Methods and compositions for detecting a target RNA |
| KR102993694B1 (ko) * | 2016-12-09 | 2026-07-22 | 더 브로드 인스티튜트, 인코퍼레이티드 | Crispr 이펙터 시스템 기반 진단 |
| US11174515B2 (en) * | 2017-03-15 | 2021-11-16 | The Broad Institute, Inc. | CRISPR effector system based diagnostics |
| US11021740B2 (en) * | 2017-03-15 | 2021-06-01 | The Broad Institute, Inc. | Devices for CRISPR effector system based diagnostics |
-
2017
- 2017-06-19 AU AU2017283713A patent/AU2017283713B2/en active Active
- 2017-06-19 US US16/310,577 patent/US11788083B2/en active Active
- 2017-06-19 CA CA3028158A patent/CA3028158A1/en active Pending
- 2017-06-19 WO PCT/US2017/038154 patent/WO2017219027A1/en not_active Ceased
- 2017-06-19 BR BR112018076190-7A patent/BR112018076190A2/pt not_active Application Discontinuation
- 2017-06-19 JP JP2018566199A patent/JP7267013B2/ja active Active
- 2017-06-19 EP EP17736810.7A patent/EP3455357A1/en active Pending
- 2017-06-19 KR KR1020197001527A patent/KR20190019168A/ko not_active Ceased
- 2017-06-19 KR KR1020237037115A patent/KR102970552B1/ko active Active
- 2017-06-19 CN CN201780050351.5A patent/CN109642231A/zh active Pending
-
2018
- 2018-11-30 AU AU2018271372A patent/AU2018271372A1/en not_active Abandoned
-
2021
- 2021-06-07 AU AU2021203747A patent/AU2021203747B2/en active Active
-
2022
- 2022-12-23 JP JP2022206177A patent/JP2023052051A/ja active Pending
-
2023
- 2023-06-13 US US18/334,046 patent/US12612620B2/en active Active
- 2023-06-13 US US18/334,074 patent/US20240191223A1/en active Pending
- 2023-06-16 JP JP2023098872A patent/JP2023134453A/ja active Pending
- 2023-06-27 AU AU2023204078A patent/AU2023204078B2/en active Active
-
2025
- 2025-05-27 JP JP2025087622A patent/JP2025138635A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102970552B1 (ko) | 2026-05-28 |
| AU2023204078B2 (en) | 2025-12-11 |
| WO2017219027A1 (en) | 2017-12-21 |
| KR20190019168A (ko) | 2019-02-26 |
| EP3455357A1 (en) | 2019-03-20 |
| CA3028158A1 (en) | 2017-12-21 |
| US20240191223A1 (en) | 2024-06-13 |
| AU2021203747A1 (en) | 2021-07-01 |
| US20190359971A1 (en) | 2019-11-28 |
| JP2019524072A (ja) | 2019-09-05 |
| US12612620B2 (en) | 2026-04-28 |
| AU2023204078A1 (en) | 2023-07-13 |
| JP7267013B2 (ja) | 2023-05-01 |
| US20230383282A1 (en) | 2023-11-30 |
| JP2023052051A (ja) | 2023-04-11 |
| AU2021203747B2 (en) | 2023-11-09 |
| US11788083B2 (en) | 2023-10-17 |
| AU2018271372A1 (en) | 2019-01-17 |
| CN109642231A (zh) | 2019-04-16 |
| AU2017283713A1 (en) | 2018-12-20 |
| JP2025138635A (ja) | 2025-09-25 |
| KR20230156150A (ko) | 2023-11-13 |
| AU2017283713B2 (en) | 2021-04-08 |
| JP2023134453A (ja) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018251801A8 (en) | Novel type VI CRISPR orthologs and systems | |
| AU2018236742B2 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| MX377162B (es) | Nuevas enzimas y sistemas crispr | |
| EP4361261A3 (en) | Novel cas13b orthologues crispr enzymes and systems | |
| WO2016205749A8 (en) | Novel crispr enzymes and systems | |
| EP4306653A3 (en) | Multiplexed optimized mismatch amplification (moma)-target number | |
| WO2017127807A8 (en) | Crystal structure of crispr cpf1 | |
| EA201991555A1 (ru) | Композиции и способы усиления или увеличения продукции ifn i типа | |
| HK1248162A1 (zh) | 因数ix融合蛋白以及其制备及使用方法 | |
| EP4389889A3 (en) | Compositions and methods for editing rna | |
| WO2016154127A3 (en) | Compositions and methods for treating hypertriglyceridemia | |
| MX2020003841A (es) | Métodos y composiciones para la producción de nucleósido trifosfatos y ácidos ribonucleicos. | |
| HK1256817A1 (zh) | 用於基因组编辑的组合物和方法 | |
| BR112016003127A2 (pt) | composições e métodos para modular rna | |
| BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
| WO2018027078A8 (en) | Adenosine nucleobase editors and uses thereof | |
| BR112019000195A2 (pt) | composições e métodos relacionados a sistemas celulares terapêuticos que expressam rna exógeno | |
| WO2015191693A3 (en) | Method for gene editing | |
| WO2016065349A8 (en) | Short non-coding protein regulatory rnas (sprrnas) and methods of use | |
| DK3607055T3 (da) | Sammensætninger til omprogrammering af celler til dendritiske celler eller antigenpræsenterende celler, fremgangsmåder og anvendelser deraf | |
| HK1252152A1 (zh) | 用於評估無細胞dna的多重優化錯配擴增(moma)實時pcr | |
| BR112018010341A2 (pt) | composição, sistema e método para tratamento do cabelo, método para alteração da cor do cabelo, e, kit de multicompartimentos para alteração da cor ou do formato do cabelo. | |
| MX2018003696A (es) | Composicion acida que comprende una ficocianina. | |
| BR112021016783A2 (pt) | Composições e métodos para tratar laminopatias | |
| MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |